search
Back to results

Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

Primary Purpose

Pain, Cancer

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
BEMA Fentanyl
Sponsored by
BioDelivery Sciences International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring Breakthrough Pain in Cancer Patients

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control. 18 years or older Patient must have pain associated with cancer or cancer treatment Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg) Regularly experience 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control At least partial relief of breakthrough pain by use of opioid therapy Subject must be able to self-administer the study medication correctly. Subject must be willing and able to complete the electronic diary card with each pain episode. Signed consent must be obtained at screening prior to any procedures being performed. Exclusion Criteria: Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study Moderate (Grade 3) to severe (Grade 4) mucositis (subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation) Strontium 89 therapy within the previous 6 months Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication. Use of an investigational drug within 4 weeks preceding this study • History of hypersensitivity or intolerance to fentanyl Regularly more than 4 episodes per day ECOG performance status of 4 or 5 Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate contraceptive measures

Sites / Locations

  • ResearchPoint

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

BEMA Fentanyl

Outcomes

Primary Outcome Measures

Percentage of Participants With Adverse Events.
After the first dose of BEMA Fentanyl, all adverse events were recorded and summarized.

Secondary Outcome Measures

Full Information

First Posted
February 15, 2006
Last Updated
September 6, 2012
Sponsor
BioDelivery Sciences International
search

1. Study Identification

Unique Protocol Identification Number
NCT00293020
Brief Title
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
Official Title
An Open Label, Long-term Treatment Evaluation of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioDelivery Sciences International

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption. BioDelivery Sciences International, Inc. (BDSI) has developed BEMA (BioErodible MucoAdhesive) fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small disc that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the disc readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the disc are water soluble, so the entire dosage form dissolves within 30 minutes of application.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Cancer
Keywords
Breakthrough Pain in Cancer Patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
244 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
BEMA Fentanyl
Intervention Type
Drug
Intervention Name(s)
BEMA Fentanyl
Other Intervention Name(s)
bioerodible mucoadhesive system
Intervention Description
buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
Primary Outcome Measure Information:
Title
Percentage of Participants With Adverse Events.
Description
After the first dose of BEMA Fentanyl, all adverse events were recorded and summarized.
Time Frame
Participants were followed for the duration of the study, an average of 126 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control. 18 years or older Patient must have pain associated with cancer or cancer treatment Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg) Regularly experience 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control At least partial relief of breakthrough pain by use of opioid therapy Subject must be able to self-administer the study medication correctly. Subject must be willing and able to complete the electronic diary card with each pain episode. Signed consent must be obtained at screening prior to any procedures being performed. Exclusion Criteria: Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study Moderate (Grade 3) to severe (Grade 4) mucositis (subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation) Strontium 89 therapy within the previous 6 months Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication. Use of an investigational drug within 4 weeks preceding this study • History of hypersensitivity or intolerance to fentanyl Regularly more than 4 episodes per day ECOG performance status of 4 or 5 Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate contraceptive measures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Blum, MD
Organizational Affiliation
BioDelivery Sciences International
Official's Role
Study Chair
Facility Information:
Facility Name
ResearchPoint
City
Austin
State/Province
Texas
ZIP/Postal Code
78746
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

We'll reach out to this number within 24 hrs